Strain Name:

B6.129P2-Trp53tm1Brn/J

Stock Number:

008462

Availability:

Repository- Live

Use Restrictions Apply, see Terms of Use
Exons 2-10 of the Trp53 (transformation related protein 53) gene are flanked by loxP sites in this conditional targeted mutation. Mice homozygous for the floxed allele do not show any increase in disease incidence for at least a year. When bred to mice with a cre recombinase gene under the control of a promoter of interest, expression is deleted in the tissue of interest.

Description

Strain Information

Type Congenic; Targeted Mutation;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Additional information on Congenic nomenclature.
Mating SystemHeterozygote x Heterozygote         (Female x Male)   21-NOV-08
Specieslaboratory mouse
GenerationN9+F1 (14-JAN-09)
 
Donating Investigator Tyler Jacks,   Massachusetts Institute of Technology

Description
Exons 2-10 are flanked by loxP sites in this conditional targeted mutation. Mice homozygous for the floxed allele do not show any increase in disease incidence for at least a year. When bred to mice with a cre recombinase gene under the control of a promoter of interest, expression is deleted in the tissue of interest.

For example, when crossed to a strain expressing Cre recombinase in the nervous system (see Stock No. 003771), this mutant mouse strain may be useful in studies of medulloblastoma formation.

When crossed to a strain expressing Cre recombinase in the central nervous system (see Stock No. 004600), this mutant mouse strain may be useful in studies of astrocytoma formation.

Development
A targeting vector was used to introduce flanking loxP sites to introns 1 and 10 of the gene. An IB10/E14IB10 129P2/OlaHsd-derived embryonic stem cell line was used to create the mutation. This line has been backcrossed to C57BL/6 for eight generations by the donating laboratory.

Control Information

  Control
   Wild-type from the colony
   000664 C57BL/6J
 
  Considerations for Choosing Controls

Related Strains

View Strains carrying other alleles of Trp53     (21 strains)

Additional Web Information

Introduction to Cre-lox technology

Phenotype

Phenotype Information

View Mammalian Phenotype Terms

Mammalian Phenotype Terms
      assigned by genotype

The following phenotype information may relate to a genetic background differing from this JAX® Mice strain.

Trp53tm1Brn/Trp53tm1Brn

        involves: 129P2/OlaHsd   (conditional)
  • cellular phenotype
  • *normal* cellular phenotype (MGI Ref ID J:117113)
    • ovarian surface epithelium (OSE) cells do not show any enhancement of proliferation after adenoviral cre treatment
    • abnormal cell death (MGI Ref ID J:117113)
      • after adenoviral cre infection, OSE cells in culture show significantly higher sensitivity to cisplatin treatment compared to control cells (31% remain ater 48 hours compared to 40% of control cells remaining)

Trp53tm1Brn/Trp53tm1Brn

        involves: 129P2/OlaHsd * FVB/N
  • normal phenotype
  • no abnormal phenotype detected (MGI Ref ID J:73028)
    • mice are normal

The following phenotype relates to a compound genotype created using this strain.
Contact JAX® Services jaxservices@jax.org for customized breeding options.

Trp53tm1Brn/Trp53tm1Brn Tg(GFAP-cre)25Mes/0

        involves: 129P2/OlaHsd * C57BL/6 * FVB/N   (conditional)
  • tumorigenesis
  • malignant tumors (MGI Ref ID J:140704)
    • 4 of 23 mice develop anaplastic astrocytomas

Trp53tm1Brn/Trp53tm1Tyj Tg(Nes-cre)1Kln/0

        involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL   (conditional)
  • tumorigenesis
  • medulloblastoma (MGI Ref ID J:102702)
    • 2/5 (40%) of mice receiving 4 Gy radiation at P5 develop cerebellar tumors by 5 months of age
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Research Tools
Cancer Research
Cre-lox System
      loxP-flanked Sequences

Trp53 related

Apoptosis Research
Endogenous Regulators

Cancer Research
Increased Tumor Incidence
      Lymphomas
      Other Tissues/Organs: osteosarcoma
Toxicology
Tumor Suppressor Genes

Immunology and Inflammation Research
Intracellular Signaling Molecules

Mouse/Human Gene Homologs
Li-Fraumeni syndrome

Research Tools
Toxicology Research
      B and T cell deficiency, xenograft transplant host
      drug/compound testing

Genes & Alleles

Gene & Allele Information

 
Allele Symbol Trp53tm1Brn
Allele Name targeted mutation 1, Anton Berns
Allele Type Targeted (Floxed/Frt)
Common Name(s) Trp53F2-10; Trp53F2-F10; Trp53Fl; p53F; p53Fl; p53L; p53LoxP; p53flox; p53lox;
Mutation Made By Anton Berns,   University of Amsterdam
Strain of Origin129P2/OlaHsd
ES Cell Line NameIB10/E14IB10
ES Cell Line Strain129P2/OlaHsd
Gene Symbol and Name Trp53, transformation related protein 53
Chromosome 11
Gene Common Name(s) FLJ92943; LFS1; MGC112612; p53;
Molecular Note Insertion of loxP sites flanking exons 2 through 10. No effect on the normal function of the gene. [MGI Ref ID J:61961]

Genotyping

Genotyping Information

Genotyping Protocols

Trp53tm1Brn, Standard PCR

Helpful Links

Genotyping resources and troubleshooting

References

References

Selected Reference(s)

Marino S; Vooijs M; van Der Gulden H; Jonkers J; Berns A. 2000. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev 14(8):994-1004. [PubMed: 10783170]  [MGI Ref ID J:61961]

Additional References

Trp53tm1Brn related

Ayrault O; Godeny MD; Dillon C; Zindy F; Fitzgerald P; Roussel MF; Beere HM. 2009. Inhibition of Hsp90 via 17-DMAG induces apoptosis in a p53-dependent manner to prevent medulloblastoma. Proc Natl Acad Sci U S A 106(40):17037-42. [PubMed: 19805107]  [MGI Ref ID J:153693]

Bailey SL; Gurley KE; Hoon-Kim K; Kelly-Spratt KS; Kemp CJ. 2008. Tumor suppression by p53 in the absence of Atm. Mol Cancer Res 6(7):1185-92. [PubMed: 18583527]  [MGI Ref ID J:139874]

Bardeesy N; Aguirre AJ; Chu GC; Cheng KH; Lopez LV; Hezel AF; Feng B; Brennan C; Weissleder R; Mahmood U; Hanahan D; Redston MS; Chin L; Depinho RA. 2006. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A 103(15):5947-52. [PubMed: 16585505]  [MGI Ref ID J:108298]

Berman SD; Calo E; Landman AS; Danielian PS; Miller ES; West JC; Fonhoue BD; Caron A; Bronson R; Bouxsein ML; Mukherjee S; Lees JA. 2008. Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc Natl Acad Sci U S A 105(33):11851-6. [PubMed: 18697945]  [MGI Ref ID J:139697]

Budanov AV; Karin M. 2008. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 134(3):451-60. [PubMed: 18692468]  [MGI Ref ID J:139563]

Calbo J; Meuwissen R; van Montfort E; van Tellingen O; Berns A. 2005. Genotype-phenotype relationships in a mouse model for human small-cell lung cancer. Cold Spring Harb Symp Quant Biol 70:225-32. [PubMed: 16869758]  [MGI Ref ID J:115156]

Caulin C; Nguyen T; Lang GA; Goepfert TM; Brinkley BR; Cai WW; Lozano G; Roop DR. 2007. An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. J Clin Invest 117(7):1893-901. [PubMed: 17607363]  [MGI Ref ID J:124222]

Chen YW; Klimstra DS; Mongeau ME; Tatem JL; Boyartchuk V; Lewis BC. 2007. Loss of p53 and Ink4a/Arf cooperate in a cell autonomous fashion to induce metastasis of hepatocellular carcinoma cells. Cancer Res 67(16):7589-96. [PubMed: 17699762]  [MGI Ref ID J:124361]

Cheung AF; Dupage MJ; Dong HK; Chen J; Jacks T. 2008. Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer. Cancer Res 68(22):9459-68. [PubMed: 19010921]  [MGI Ref ID J:141383]

Clark-Knowles KV; Garson K; Jonkers J; Vanderhyden BC. 2007. Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. Exp Cell Res 313(1):133-45. [PubMed: 17070800]  [MGI Ref ID J:117113]

Daikoku T; Hirota Y; Tranguch S; Joshi AR; DeMayo FJ; Lydon JP; Ellenson LH; Dey SK. 2008. Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice. Cancer Res 68(14):5619-27. [PubMed: 18632614]  [MGI Ref ID J:139053]

Daikoku T; Tranguch S; Trofimova IN; Dinulescu DM; Jacks T; Nikitin AY; Connolly DC; Dey SK. 2006. Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Res 66(5):2527-31. [PubMed: 16510568]  [MGI Ref ID J:106703]

Dankort D; Filenova E; Collado M; Serrano M; Jones K; McMahon M. 2007. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 21(4):379-84. [PubMed: 17299132]  [MGI Ref ID J:121715]

Derksen PW; Liu X; Saridin F; van der Gulden H; Zevenhoven J; Evers B; van Beijnum JR; Griffioen AW; Vink J; Krimpenfort P; Peterse JL; Cardiff RD; Berns A; Jonkers J. 2006. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 10(5):437-49. [PubMed: 17097565]  [MGI Ref ID J:116152]

Flesken-Nikitin A; Choi KC; Eng JP; Shmidt EN; Nikitin AY. 2003. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res 63(13):3459-63. [PubMed: 12839925]  [MGI Ref ID J:84345]

Gidekel Friedlander SY; Chu GC; Snyder EL; Girnius N; Dibelius G; Crowley D; Vasile E; DePinho RA; Jacks T. 2009. Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell 16(5):379-89. [PubMed: 19878870]  [MGI Ref ID J:153948]

Gil-Perotin S; Marin-Husstege M; Li J; Soriano-Navarro M; Zindy F; Roussel MF; Garcia-Verdugo JM; Casaccia-Bonnefil P. 2006. Loss of p53 induces changes in the behavior of subventricular zone cells: implication for the genesis of glial tumors. J Neurosci 26(4):1107-16. [PubMed: 16436596]  [MGI Ref ID J:104815]

Greenow KR; Clarke AR; Jones RH. 2009. Chk1 deficiency in the mouse small intestine results in p53-independent crypt death and subsequent intestinal compensation. Oncogene 28(11):1443-53. [PubMed: 19169280]  [MGI Ref ID J:147589]

Hammoud Z; Tan B; Badve S; Bigsby RM. 2008. Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma. Endocr Relat Cancer 15(2):475-83. [PubMed: 18509000]  [MGI Ref ID J:149009]

Hasselblatt P; Rath M; Komnenovic V; Zatloukal K; Wagner EF. 2007. Hepatocyte survival in acute hepatitis is due to c-Jun/AP-1-dependent expression of inducible nitric oxide synthase. Proc Natl Acad Sci U S A 104(43):17105-10. [PubMed: 17940019]  [MGI Ref ID J:125913]

Hay T; Matthews JR; Pietzka L; Lau A; Cranston A; Nygren AO; Douglas-Jones A; Smith GC; Martin NM; O'Connor M; Clarke AR. 2009. Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res 69(9):3850-5. [PubMed: 19383921]  [MGI Ref ID J:148266]

Hinkal G; Parikh N; Donehower LA. 2009. Timed somatic deletion of p53 in mice reveals age-associated differences in tumor progression. PLoS One 4(8):e6654. [PubMed: 19680549]  [MGI Ref ID J:152463]

Jackson EL; Olive KP; Tuveson DA; Bronson R; Crowley D; Brown M; Jacks T. 2005. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 65(22):10280-8. [PubMed: 16288016]  [MGI Ref ID J:103407]

Ji H; Ramsey MR; Hayes DN; Fan C; McNamara K; Kozlowski P; Torrice C; Wu MC; Shimamura T; Perera SA; Liang MC; Cai D; Naumov GN; Bao L; Contreras CM; Li D; Chen L; Krishnamurthy J; Koivunen J; Chirieac LR; Padera RF; Bronson RT; Lindeman NI; Christiani DC; Lin X; Shapiro GI; Janne PA; Johnson BE; Meyerson M; Kwiatkowski DJ; Castrillon DH; Bardeesy N; Sharpless NE; Wong KK. 2007. LKB1 modulates lung cancer differentiation and metastasis. Nature 448(7155):807-10. [PubMed: 17676035]  [MGI Ref ID J:124682]

Johnson DA; Zhang J; Frase S; Wilson M; Rodriguez-Galindo C; Dyer MA. 2007. Neuronal differentiation and synaptogenesis in retinoblastoma. Cancer Res 67(6):2701-11. [PubMed: 17363591]  [MGI Ref ID J:120315]

Jongsma J; van Montfort E; Vooijs M; Zevenhoven J; Krimpenfort P; van der Valk M; van de Vijver M; Berns A. 2008. A conditional mouse model for malignant mesothelioma. Cancer Cell 13(3):261-71. [PubMed: 18328429]  [MGI Ref ID J:132943]

Jonkers J; Meuwissen R; van Der Gulden H; Peterse H; van Der Valk M; Berns A. 2001. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 29(4):418-25. [PubMed: 11694875]  [MGI Ref ID J:73028]

Keller C; Arenkiel BR; Coffin CM; El-Bardeesy N; DePinho RA; Capecchi MR. 2004. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev 18(21):2614-26. [PubMed: 15489287]  [MGI Ref ID J:93444]

Kirsch DG; Dinulescu DM; Miller JB; Grimm J; Santiago PM; Young NP; Nielsen GP; Quade BJ; Chaber CJ; Schultz CP; Takeuchi O; Bronson RT; Crowley D; Korsmeyer SJ; Yoon SS; Hornicek FJ; Weissleder R; Jacks T. 2007. A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med 13(8):992-7. [PubMed: 17676052]  [MGI Ref ID J:125101]

Laurie NA; Donovan SL; Shih CS; Zhang J; Mills N; Fuller C; Teunisse A; Lam S; Ramos Y; Mohan A; Johnson D; Wilson M; Rodriguez-Galindo C; Quarto M; Francoz S; Mendrysa SM; Guy RK; Marine JC; Jochemsen AG; Dyer MA. 2006. Inactivation of the p53 pathway in retinoblastoma. Nature 444(7115):61-6. [PubMed: 17080083]  [MGI Ref ID J:115580]

Lechel A; Holstege H; Begus Y; Schienke A; Kamino K; Lehmann U; Kubicka S; Schirmacher P; Jonkers J; Rudolph KL. 2007. Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease. Gastroenterology 132(4):1465-75. [PubMed: 17433324]  [MGI Ref ID J:128326]

Lin PP; Pandey MK; Jin F; Raymond AK; Akiyama H; Lozano G. 2009. Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice. Carcinogenesis 30(10):1789-95. [PubMed: 19635748]  [MGI Ref ID J:153430]

Lin PP; Pandey MK; Jin F; Xiong S; Deavers M; Parant JM; Lozano G. 2008. EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model. Cancer Res 68(21):8968-75. [PubMed: 18974141]  [MGI Ref ID J:140636]

Linnoila RI; Naizhen X; Meuwissen R; Berns A; DeMayo FJ. 2005. Mouse lung neuroendocrine carcinomas: distinct morphologies, same transcription factors. Exp Lung Res 31(1):37-55. [PubMed: 15765918]  [MGI Ref ID J:97849]

Liu X; Holstege H; van der Gulden H; Treur-Mulder M; Zevenhoven J; Velds A; Kerkhoven RM; van Vliet MH; Wessels LF; Peterse JL; Berns A; Jonkers J. 2007. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A 104(29):12111-6. [PubMed: 17626182]  [MGI Ref ID J:126551]

Marino S; Hoogervoorst D; Brandner S; Berns A. 2003. Rb and p107 are required for normal cerebellar development and granule cell survival but not for Purkinje cell persistence. Development 130(15):3359-68. [PubMed: 12810584]  [MGI Ref ID J:83783]

Martinez-Cruz AB; Santos M; Lara MF; Segrelles C; Ruiz S; Moral M; Lorz C; Garcia-Escudero R; Paramio JM. 2008. Spontaneous squamous cell carcinoma induced by the somatic inactivation of retinoblastoma and Trp53 tumor suppressors. Cancer Res 68(3):683-92. [PubMed: 18245467]  [MGI Ref ID J:131867]

Meuwissen R; Linn SC; Linnoila RI; Zevenhoven J; Mooi WJ; Berns A. 2003. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 4(3):181-9. [PubMed: 14522252]  [MGI Ref ID J:86077]

Moral M; Segrelles C; Lara MF; Martinez-Cruz AB; Lorz C; Santos M; Garcia-Escudero R; Lu J; Kiguchi K; Buitrago A; Costa C; Saiz C; Rodriguez-Peralto JL; Martinez-Tello FJ; Rodriguez-Pinilla M; Sanchez-Cespedes M; Garin M; Grande T; Bravo A; DiGiovanni J; Paramio JM. 2009. Akt activation synergizes with Trp53 loss in oral epithelium to produce a novel mouse model for head and neck squamous cell carcinoma. Cancer Res 69(3):1099-108. [PubMed: 19176372]  [MGI Ref ID J:144831]

Morton JP; Klimstra DS; Mongeau ME; Lewis BC. 2008. Trp53 deletion stimulates the formation of metastatic pancreatic tumors. Am J Pathol 172(4):1081-7. [PubMed: 18310506]  [MGI Ref ID J:133144]

Nishijo K; Chen QR; Zhang L; McCleish AT; Rodriguez A; Cho MJ; Prajapati SI; Gelfond JA; Chisholm GB; Michalek JE; Aronow BJ; Barr FG; Randall RL; Ladanyi M; Qualman SJ; Rubin BP; LeGallo RD; Wang C; Khan J; Keller C. 2009. Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma. Cancer Res 69(7):2902-11. [PubMed: 19339268]  [MGI Ref ID J:147341]

Nolan-Stevaux O; Lau J; Truitt ML; Chu GC; Hebrok M; Fernandez-Zapico ME; Hanahan D. 2009. GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev 23(1):24-36. [PubMed: 19136624]  [MGI Ref ID J:143478]

Puzio-Kuter AM; Castillo-Martin M; Kinkade CW; Wang X; Shen TH; Matos T; Shen MM; Cordon-Cardo C; Abate-Shen C. 2009. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 23(6):675-80. [PubMed: 19261747]  [MGI Ref ID J:146760]

Raimondi AR; Molinolo A; Gutkind JS. 2009. Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model. Cancer Res 69(10):4159-66. [PubMed: 19435901]  [MGI Ref ID J:148476]

Rottenberg S; Nygren AO; Pajic M; van Leeuwen FW; van der Heijden I; van de Wetering K; Liu X; de Visser KE; Gilhuijs KG; van Tellingen O; Schouten JP; Jonkers J; Borst P. 2007. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci U S A 104(29):12117-22. [PubMed: 17626183]  [MGI Ref ID J:126564]

Savic V; Yin B; Maas NL; Bredemeyer AL; Carpenter AC; Helmink BA; Yang-Iott KS; Sleckman BP; Bassing CH. 2009. Formation of dynamic gamma-H2AX domains along broken DNA strands is distinctly regulated by ATM and MDC1 and dependent upon H2AX densities in chromatin. Mol Cell 34(3):298-310. [PubMed: 19450528]  [MGI Ref ID J:150434]

Shai A; Pitot HC; Lambert PF. 2008. p53 Loss synergizes with estrogen and papillomaviral oncogenes to induce cervical and breast cancers. Cancer Res 68(8):2622-31. [PubMed: 18413729]  [MGI Ref ID J:133964]

Shakhova O; Leung C; van Montfort E; Berns A; Marino S. 2006. Lack of Rb and p53 delays cerebellar development and predisposes to large cell anaplastic medulloblastoma through amplification of N-Myc and Ptch2. Cancer Res 66(10):5190-200. [PubMed: 16707443]  [MGI Ref ID J:109060]

Shanker A; Brooks AD; Jacobsen KM; Wine JW; Wiltrout RH; Yagita H; Sayers TJ. 2009. Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity. Cancer Res 69(16):6615-23. [PubMed: 19654302]  [MGI Ref ID J:151764]

Siwko SK; Bu W; Gutierrez C; Lewis B; Jechlinger M; Schaffhausen B; Li Y. 2008. Lentivirus-mediated oncogene introduction into mammary cells in vivo induces tumors. Neoplasia 10(7):653-62, 1 p following 662. [PubMed: 18592025]  [MGI Ref ID J:140428]

Uziel T; Zindy F; Xie S; Lee Y; Forget A; Magdaleno S; Rehg JE; Calabrese C; Solecki D; Eberhart CG; Sherr SE; Plimmer S; Clifford SC; Hatten ME; McKinnon PJ; Gilbertson RJ; Curran T; Sherr CJ; Roussel MF. 2005. The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. Genes Dev 19(22):2656-67. [PubMed: 16260494]  [MGI Ref ID J:102702]

Walkley CR; Qudsi R; Sankaran VG; Perry JA; Gostissa M; Roth SI; Rodda SJ; Snay E; Dunning P; Fahey FH; Alt FW; McMahon AP; Orkin SH. 2008. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev 22(12):1662-76. [PubMed: 18559481]  [MGI Ref ID J:136693]

Wei H; Gan B; Wu X; Guan JL. 2009. Inactivation of FIP200 leads to inflammatory skin disorder, but not tumorigenesis, in conditional knock-out mouse models. J Biol Chem 284(9):6004-13. [PubMed: 19106106]  [MGI Ref ID J:147901]

Weiss WA; Israel M; Cobbs C; Holland E; James CD; Louis DN; Marks C; McClatchey AI; Roberts T; Van Dyke T; Wetmore C; Chiu IM; Giovannini M; Guha A; Higgins RJ; Marino S; Radovanovic I; Reilly K; Aldape K. 2002. Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum. Oncogene 21(49):7453-63. [PubMed: 12386807]  [MGI Ref ID J:79667]

Xing D; Scangas G; Nitta M; He L; Xu X; Ioffe YJ; Aspuria PJ; Hedvat CY; Anderson ML; Oliva E; Karlan BY; Mohapatra G; Orsulic S. 2009. A role for BRCA1 in uterine leiomyosarcoma. Cancer Res 69(21):8231-5. [PubMed: 19843854]  [MGI Ref ID J:153954]

Xiong S; Van Pelt CS; Elizondo-Fraire AC; Fernandez-Garcia B; Lozano G. 2007. Loss of Mdm4 results in p53-dependent dilated cardiomyopathy. Circulation 115(23):2925-30. [PubMed: 17533180]  [MGI Ref ID J:137114]

Zhang J; Schweers B; Dyer MA. 2004. The first knockout mouse model of retinoblastoma. Cell Cycle 3(7):952-9. [PubMed: 15190215]  [MGI Ref ID J:103618]

Zhao H; Ayrault O; Zindy F; Kim JH; Roussel MF. 2008. Post-transcriptional down-regulation of Atoh1/Math1 by bone morphogenic proteins suppresses medulloblastoma development. Genes Dev 22(6):722-727. [PubMed: 18347090]  [MGI Ref ID J:132983]

Zheng H; Ying H; Yan H; Kimmelman AC; Hiller DJ; Chen AJ; Perry SR; Tonon G; Chu GC; Ding Z; Stommel JM; Dunn KL; Wiedemeyer R; You MJ; Brennan C; Wang YA; Ligon KL; Wong WH; Chin L; DePinho RA. 2008. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 455(7216):1129-33. [PubMed: 18948956]  [MGI Ref ID J:140704]

Zhou Z; Flesken-Nikitin A; Corney DC; Wang W; Goodrich DW; Roy-Burman P; Nikitin AY. 2006. Synergy of p53 and Rb Deficiency in a Conditional Mouse Model for Metastatic Prostate Cancer. Cancer Res 66(16):7889-98. [PubMed: 16912162]  [MGI Ref ID J:112104]

Zhou Z; Flesken-Nikitin A; Nikitin AY. 2007. Prostate Cancer Associated with p53 and Rb Deficiency Arises from the Stem/Progenitor Cell-Enriched Proximal Region of Prostatic Ducts. Cancer Res 67(12):5683-90. [PubMed: 17553900]  [MGI Ref ID J:122263]

Zindy F; Uziel T; Ayrault O; Calabrese C; Valentine M; Rehg JE; Gilbertson RJ; Sherr CJ; Roussel MF. 2007. Genetic alterations in mouse medulloblastomas and generation of tumors de novo from primary cerebellar granule neuron precursors. Cancer Res 67(6):2676-84. [PubMed: 17363588]  [MGI Ref ID J:120317]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Room Number           AX11

Colony Maintenance

Breeding & HusbandryWhen maintained as a live colony, heterozygotes may be bred. Homozygotes have a somewhat reduced fertility, but may be bred.
Mating SystemHeterozygote x Heterozygote         (Female x Male)   21-NOV-08
Diet Information LabDiet® 5K52/5K67

Purchasing information

Pricing, Supply Level & Notes, Controls, General Terms & Conditions

Pricing

Pricing for USA, Canada and Mexico shipping destinations View International pricing
Weeks of AgePrice (US dollars $)GenderGenotypes Provided
Individual Mouse $243.50Female or MaleHeterozygous for Trp53tm1Brn
Pairs /Price (US dollars $)Pair Genotype
$487.00Heterozygous for Trp53tm1Brn x Heterozygous for Trp53tm1Brn

Additional Supply Details

Pricing for International shipping destinations View USA Canada and Mexico pricing
Weeks of AgePrice (US dollars $)GenderGenotypes Provided
Individual Mouse $316.60Female or MaleHeterozygous for Trp53tm1Brn
Pairs /Price (US dollars $)Pair Genotype
$633.10Heterozygous for Trp53tm1Brn x Heterozygous for Trp53tm1Brn

Additional Supply Details

Supply Details

Standard SupplyRepository-Live. A collection of over 1000 strains maintained as live colonies. Individual colonies are sized to meet current customer demand. Delivery for orders of 10 mice or less ranges on average from one to eight weeks; mice are generally shipped between four to six weeks of age with a maximum shipping age of approximately nine weeks. Colony sizes do not generally support stringent age specifications for large volumes of mice; however custom orders and larger quantities of mice are easily arranged. Estimated ship dates for all orders provided within two business days following order placement.
Supply Notes

Control Information

  Control
   Wild-type from the colony
   000664 C57BL/6J
 
  Considerations for Choosing Controls
  USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains.
  International - Control Pricing Information for Genetically Engineered Mutant Strains.

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering and Purchasing Information

      Purchasing Information
      JAX® Mice Orders
      Surgical Services

Contact Information
Orders & Technical Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


P53 Mice are subject to U.S. 5,569,824 and corresponding license requirements.

Contact information

General inquiries

Contracts Administration

phone:207-288-6470
fax:207-288-6655

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. In purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(3.12)